In patients with breast ductal adenocarcinoma, a negative correlation was observed between the degree of GSDME methylation and 5-year overall survival (OS), indicating that GSDME methylation is a prospective biomarker for determining prognosis [88]. This evidence concerns the gene GSDME and breast ductal adenocarcinoma.